Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Biomics Biotech Closes 34 Million RMB B Round

publication date: Aug 26, 2008

Biomics Biotechnologies (Nantong) Co., a company focused on RNAi drug R&D, closed a Series B funding of 34 million RMB ($5 million) on July 31 2008. The financing follows the company’s $3.5 million Series A round of January 2007, according to Zero2IPO. The B round was led by Jiangsu Dinghong Venture Capital Co., Ltd., with Jiangsu Benefit Rise Group also participating. More details...



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital